World Lung 2023 – Flaura2 leaves a gap open for J&J
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
World Lung 2023 – targeted therapy to the rescue in small-cell lung
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
No end in sight for antibody-drug conjugate enthusiasm
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
Olema takes its antagonist/degrader concept into phase 3
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
